Heat shock protein 70-2 (HSP70-2) overexpression in breast cancer by Nirmala Jagadish et al.
RESEARCH Open Access
Heat shock protein 70-2 (HSP70-2)
overexpression in breast cancer
Nirmala Jagadish1, Sumit Agarwal1, Namita Gupta1, Rukhsar Fatima1, Sonika Devi1, Vikash Kumar1, Vaishali Suri2,
Rajive Kumar3, Vitusha Suri4, Trilok Chand Sadasukhi4, Anju Gupta5, Abdul S. Ansari6, Nirmal Kumar Lohiya6
and Anil Suri1*
Abstract
Background: Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing
rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2
with breast cancer.
Methods: HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT)
specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR,
immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven
short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence,
migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling
cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo
human breast xenograft mouse model.
Results: HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes,
stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and
SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in
cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the
xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin
dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors,
caspases, pro-apoptotic molecules and epithelial markers.
Conclusions: HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast
cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment.
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Background
Breast cancer is the second leading cause of cancer related
deaths among women worldwide [1]. Breast cancers are
mostly adenocarcinomas which include invasive type such
as infiltrating ductal carcinoma (IDC) and non-invasive
type, Ductal Carcinoma in-situ (DCIS) [2]. IDC is the
most common subtype of breast cancer accounting for
75–80 % of all the cases diagnosed [3]. Breast cancer
incidence is highest in developed countries and increasing
rapidly in developing countries due to lack of adequate
medical support and infrastructure [4]. Therefore, there is
a need to characterize a tumor-associated molecule for
early detection of breast cancer and for identifying a novel
therapeutic target for better cancer treatment.
Heat shock family of proteins (HSPs) is proposed to
play pivotal role in breast tumor development owing to
their intrinsic molecular chaperone properties [5]. HSPs
are mainly involved in protein folding, assembly of
multiprotein complexes, protein transport and protein
targeting for lysosomal degradation [5]. Few of the HSPs
have been reported in breast cancer which includes
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HSP27, HSP90 and HSP70 [6–8]. HSP70 family has
eight members with high homology but different cellular
localization and biological functions [8]. HSP70-2, a new
member of cancer testis (CT) antigen family and an also
an important member of HSP70 family has been found
to be associated with various malignancies [8–11]. How-
ever, the clinical relevance and association of HSP70-2
expression in IDC specimens have not been investigated
so far.
Our earlier studies have shown a close association of
HSP70-2 with cellular proliferation, migration, invasion
and tumor growth in urothelial [9] and cervical cancer
[10]. In the present study, we have investigated the pos-
sible association of HSP70-2 mRNA and protein expres-
sion with various stages, grades and histotypes of breast
cancer patients. In addition, we have examined the puta-
tive role of HSP70-2 in apoptosis, cell cycle arrest and
epithelial-mesenchymal transition (EMT) in-vitro and
in-vivo xenograft mouse model using gene silencing ap-
proach. Here we provide evidence that HSP70-2 expres-
sion is associated with IDC histotype of breast cancer.
We also report that HSP70-2 plays an important role in
cellular growth, migration and invasion of breast cancer
cells and tumor growth of breast cancer xenograft. At
molecular level, we show that HSP70-2 depletion resulted
in up-regulation of caspases, pro-apoptotic molecules,
cyclin dependent kinase (CDK) inhibitors and epithelial
markers, and down-regulation of anti-apoptotic mole-
cules, cyclins, CDKs and mesenchymal markers. These
results collectively suggest that HSP70-2 could be used as




The tumor specimens from 154 patients and 103 matched
available adjacent non-cancerous tissue (ANCT) speci-
mens were collected during surgical procedure at All
India Institute of medical Sciences (AIIMS), New Delhi;
Mahatma Gandhi Medical Hospital, Jaipur. All tumor
specimens were collected from new patients who had
not undergone treatment before surgery (study period
2008–2014). Details of specimens are illustrated in Table 1.
The study was conducted as per the Ethical Committee
approval obtained from AIIMS, Mahatma Gandhi Medical
Hospital, Jaipur and National Institute of Immunology,
New Delhi. The duly signed consent forms were obtained
from the patients prior to the study.
Cell lines
Four breast cancer cell lines of different hormone
receptor profile, MCF7 (luminal-A, ER+PR+Her2−),
BT-474 (luminal-B, ER+PR+Her2+), SK-BR-3 (HER2
overexpressing, ER−PR−Her2+) and MDA-MB-231 (highly
metastatic basal, triple-negative ER−PR−Her2−) were pro-
cured from American Type Culture Collection (ATCC,
Manassas, VA). All the cells were cultured in recommended
medium under standard conditions. Human normal mam-
mary epithelial cells (HNMEC’s) were purchased and main-
tained according to manufacturer’s directions (Gibco, Life
Technologies Corporation, Carlsbad, CA).
RT-PCR, Real time-PCR analysis, Western blotting, flow
cytometric analysis and immunofluorescence,
immunohistochemistry
HSP70-2 mRNA and protein expression was examined
in tumor specimens and all four breast cancer cell lines
along with HNMEC’s as detailed in Additional file 1 and
Methods section.
Immunoreactivity score (IRS)
Immunoreactivity score (IRS) was calculated as a percent-
age of cells expressing HSP70-2 protein. For determining
the IRS, the tissue section slides were independently
reviewed by two senior pathologists. More than 500 cells
were counted from five random fields at 400× magnifica-
tions. Specimens showing >10 % HSP70-2 positive cells
were considered as positive immuno-reactive specimens.
Table 1 HSP70-2 expression (RT-PCR/IHC) and clinico-pathologic
characteristics of breast cancer
Pathologic and clinical features RT-PCR (%) IHC (%) P value
All tumors 128/154 (83) 128/154 (83) 0.569
Histotypes
DCIS 8/8 (100) 8/8 (100)
IDC 116/139 (83.4) 116/139 (83.4)
ILC 4/5 (80) 4/5 (80)
DCIS + IDC 2/2 (100) 2/2 (100)
Tumor stages (IDC)
Stage I 3/3 (100) 3/3 (100)
Stage II 68/85 (80) 68/85 (80) 0.388
Stage III 39/45 (86.7) 39/45 (86.7) 0.343
Stage IV 6/6 (100) 6/6 (100) 0.341
Stages
Early Stages (I + II) 71/88 (80.7) 71/88 (80.7) 0.248
Late Stages (III + IV) 45/51 (88.2) 45/51 (88.2)
Grades
Grade 1 62/69 (89.8) 62/69 (89.8)
Grade 2 39/52 (75) 39/52 (75) 0.029*
Grade 3 15/18 (83.3) 15/18 (83.3) 0.468
Lymph node involvement
Positive 40/51 (78.4) 40/51 (78.4)
Negative 76/88 (86.4) 76/88 (86.4)
*p < 0.017, Bonferroni correction value
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Validation of shRNA targets against HSP70-2
Four shRNA constructs against HSP70-2 along with
scrambled negative control NC shRNA were procured
from Super Array (Frederick, MD, USA) as detailed earlier
[9]. The transient transfections were carried out in
MCF7 and MDA-MB-231 cells using lipofectamine
(Invitrogen Life Technologies Corporation, USA) and
HSP70-2 knockdown efficiency was determined by
Real-time PCR and Western blotting as described in
Additional file 1 and Methods section.
Cellular proliferation analysis, cell viability and colony
formation assay
Cellular proliferation, viability and colony forming assay
was carried in HSP70-2 shRNA3, shRNA4 and NC shRNA
transfected MCF7 and MDA-MB-231 cells out as detailed
in Additional file 1 and Methods section.
Cell cycle analysis
The HSP70-2 shRNA3, shRNA4 and NC shRNA trans-
fected MDA-MB-231 cells were fixed in ethanol and
stained with propidium iodide with RNaseA as described
earlier [12]. The cells were analyzed by flow cytometry
on BD-VERSA (BD Biosciences, California, USA).
Cellular senescence assay
HSP70-2 shRNA3, shRNA4 and NC shRNA transfected
MDA-MB-231 cells were stained with X-gal using
Senescence kit (Sigma-Aldrich, St. Louis, MO, USA) as
per manufacturer’s instructions. The images were cap-
tured using Nikon Eclipse E400 microscope (Nikon,
Fukok, Japan).
Scanning electron microscopy
MDA-MB-231 and MCF7 cells were treated with lipo-
fectamine, DMSO, HSP70-2 shRNA3, shRNA4 and NC
shRNA. The cells were processed as described earlier
[13]. The images were captured using electron microscope
(EVO LSM10 Zeiss, Germany) at 20 kV using SmartSEM
software in central microscopic facility.
TUNEL assay
DNA fragmentation due to shRNA treatment was studied
using Apo-BrdU-Red In-situ DNA fragmentation assay kit
(Biovision, California, USA). HSP70-2 shRNA3, shRNA4
and NC shRNA transfected MDA-MB-231 cells were
processed as described earlier [13]. The cells were ana-
lyzed at 576 nm using BD-FACS VERSA. (BD Biosciences,
California, USA).
M30 assay
HSP70-2 shRNA3, shRNA4 and NC shRNA trans-
fected MDA-MB-231 cells were fixed with methanol
and M30 assay was carried using M30 cytoDEATH
antibody (Roche Diagnostics, GmBH, Mannheim,
Germany). The cells were analyzed using BD-FACS
VERSA. (BD Biosciences, California, USA).
Chromatin condensation assay
HSP70-2 shRNA3, shRNA4 and NC shRNA transfected
MDA-MB-231 cells were harvested, washed with PBS
and stained with 5 μg/ml of DAPI for 3 min at 37 °C.
The level of chromatin condensation was determined by
flow cytometry using BD-FACS VERSA (BD Biosciences,
California, USA).
AnnexinV staining
To study the effect of HSP70-2 shRNA3 and shRNA4 on
apoptosis compared to NC shRNA, MDA-MB-231 cells
were stained with annexinV using annexinV-PerCP-Cy5-5-
A staining kit (Biovision, CA, USA) and assay carried out
as described earlier [13].
Mitochondrial membrane potential
MDA-MB-231 cells transfected with NC shRNA, HSP70-2
shRNA3 and shRNA4 were stained with 500 nM tetra-
methyl rhodamine ethyl ester (TMRE Assay kit, Abcam,
Cambridge, United Kingdom) for 2 min at 37 °C. Mito-
chondrial membrane potential was analyzed using BD-
FACS VERSE (BD Biosciences, California, USA).
Cell migration, invasion and wound healing assay
Cell migration, invasion and wound healing ability of
HSP70-2 shRNA3, shRNA4 and NC shRNA transfected
MCF7 and MDA-MB-231 cells were assessed as described
in Additional file 1 and Methods section.
In-vivo xenograft studies
Athymic nude mice (National Institute of Immunology
[NII], National Institutes of Health, [S] nu/nu) were used
for the xenograft studies. Mice were injected subcutane-
ously with 5 × 106 MDA-MB-231 cells. The experiment
was conducted as described in Additional file 1 and
Methods section.
Statistical analysis
The statistical analysis was performed using SPSS 20.0
statistical software package (SPSS Inc, Chicago, IL, USA).
Pearson’s Chi-Square test was performed among various
grades and stages. P-values ≤ 0.017 among grades and
P-value ≤ 0.013 were considered as statistically signifi-
cant after applying a Bonferroni correction for multiple
comparisons. Based on immuno-reactivity score (IRS),
the IDC specimens were divided in; Group I including
specimens with >50 % cells expressing HSP70-2 protein,
Group II; including specimens with <50 % cells expressing
this protein. The statistical difference of HSP70-2 protein
expressing cells in group I and group II was determined
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by Mann Whitney test. Statistical comparisons of mean
values in cell line study were performed using Student’s
t-test. A P-value <0.05 was considered statistically sig-
nificant. Data is expressed as mean ± standard error of
three independent experiments in triplicates in in-vitro
assays.
Results
HSP70-2 is overexpressed in clinical samples of
breast tumors
The expression of HSP70-2 mRNA and protein was
examined in breast clinical cancer specimens by qRT-PCR
and IHC respectively. HSP70-2 gene expression was
detected in 83 % (128/154) of total breast cancer tissue
specimens irrespective of clinicopathological features of
breast cancer tissue specimens including histotypes, stages
and grades but not in ANCT samples (Fig. 1a, Table 1).
Congruent with RT-PCR data HSP70-2 protein expression
was also detected in 83 % (128/154) tissue specimens
(Fig. 1b) but not in matched ANCT (Additional file 2:
Figure S1a, c). Notably, HSP70-2 expression was ob-
served in 100 % of (8/8) DCIS, 83.4 % (116/139) of IDC,
80 % (4/5) of ILC and 100 % (2/2) of DCIS + IDC speci-
mens. Furthermore, HSP70-2 expression was found in
100 % (3/3) of stage I, 80 % (68/85) of stage II, 86.7 %
(39/45) of stage III and 100 % (6/6) stage IV of IDC
Fig. 1 HSP70-2 gene and protein expression in clinical specimens and breast cancer cell. a Representative gel picture of RT-PCR analysis shows
HSP70-2 gene expression in different histotypes (DCIS, IDC, ILC), stages (I-IV) and grades (1–3) of breast cancer specimens. b Representative images of
IHC analysis of tissue sections show HSP70-2 protein expression (chocolate brown reactivity) in different histotypes (DCIS, IDC, ILC), stages (I-IV) and
grades (1–3) of breast cancer specimens DCIS: Ductal Carcinoma in-situ, IDC: Infiltrating Ductal carcinoma and ILC: Infiltrating Lobular Carcinoma.
Objective: ×20, Magnification: ×200. c RT-PCR analysis shows HSP70-2 gene expression in breast cancer cells: BT-474, MCF7, MDA-MB-231 and SK-BR-3.
However, no HSP70-2 gene expression was observed in human normal mammary epithelial cells (HNMEC’s). Testis was used as positive control and
β-actin as loading control. d Histogram shows the qPCR analysis depicting higher expression of HSP70-2 gene in breast cancer cells as compared to
HNMECs. e Western blot analysis shows HSP70-2 protein expression in all breast cancer cells compared to no expression in HNMECs. f Flow cytometric
analysis showed surface localization (displacement of fluorescence intensity on X-axis) of HSP70-2 protein in all breast cancer cells. Red peak
shows unstained population, black peak shows cell population stained with control IgG antibody and green peak shows cell population
probed with anti-HSP70-2 antibody. g IIF depicts co-localization (yellow-orange staining) of HSP70-2 in endoplasmic reticulum, mitochondria
and Golgi bodies. However, no co-localization was observed in nuclear envelope. Nucleus is stained with DAPI. Objective: ×63, Magnification: ×630
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histotypes of tissue specimens. HSP70-2 expression was
detected in 89.8 % (62/69) of grade 1, 75 % (39/52) of grade
2 and 83.3 % (15/18) of grade 3 IDC specimens (Table 1).
In addition, 80.4 % (41/51) of IDC specimens were found
positive for HSP70-2 expression that had lymph node in-
volvement (stage III and IV), whereas, 86.4 % (76/88)
specimens with negative lymph node involvement (stage I
and II) showed HSP70-2 expression (Table 1).
Based on immuno-reactivity score (IRS), the IDC
specimens were divided in two groups as shown in
Additional file 2: Figure S1d. Group I included speci-
mens with >50 % cells expressing HSP70-2 protein,
whereas, Group II included specimens with <50 %
cells expressing this protein. Interestingly, number of
patients (75.9 %, 88/116) expressing HSP70-2 was signifi-
cantly higher (P < 0.0001) in Group I (IRS = 72.74 ± 1.34)
compared to Group II patients (24.1 %, 28/116, IRS =
28.07 ± 1.89, Additional file 2: Figure S1d) irrespective of
stages, grades and histotypes. Based on the HSP70-2 IRS
score, after the Bonferroni correction for multiple com-
parisons, HSP70-2 protein expression were found to be
significantly associated with grade 1 (63.71 ± 2.61) and
grade 2 cases (63.74 ± 3.69, P < 0.029; Table 1). In addition,
HSP70-2 protein expressing cells in patients with positive
lymph node involvement (55.33 ± 3.44) and negative
lymph node involvement (65.64 ± 2.56) was also observed.
HSP70-2 is over-expressed in breast cancer cell lines
Since breast tumor samples showed overexpression of
HSP70-2 mRNA as well as protein, we next examined
its expression in four different breast cancer cell lines
viz., BT-474, MCF7, MDA-MB-231 and SK-BR-3. As
shown in Fig. 1c, HSP70-2 mRNA expression was de-
tected in all four breast cancer cells irrespective of their
molecular phenotype but not in human normal mammary
epithelial cells (HNMEC; Fig. 1c). There was higher HSP70-
2 mRNA expression in triple negative MDA-MB-231
(>7 fold; P < 0.001) cells, followed by MCF7 (>3fold;
P < 0.001), SK-BR-3 (>3 fold; P < 0.001) and BT-474
(1.28 fold; P < 0.05) with respect to HNMEC (Fig. 1d).
Further Western blot analysis confirmed the expression of
HSP70-2 protein in in all cell lines (Fig. 1e) along with
their surface localization (Fig. 1f). In addition, we also ob-
served cytoplasmic presence of HSP70-2 in all these cells
(Additional file 2: Figure S1e) with specific localization in
endoplasmic reticulum, mitochondria and Golgi bodies
but not with nuclear envelope (Fig. 1g).
Down-regulation of HSP70-2 leads to reduced cellular
proliferation, cell viability, colony forming ability of breast
cancer cells
Interestingly we observed the overexpression of HSP70-2
in breast tumor as well as in breast cancer cell lines, there-
fore we next investigated its physiological relevance in
oncogenic properties of cancer cells. Knock-down HSP70-
2 expression was examined employing four HSP70-2
shRNA targets and scrambled shRNA (NC shRNA) in
MCF7 and MDA-MB-231 cancer cells. Our qPCR and
Western blot analysis clearly showed that HSP70-2 gene
and protein expression was specifically down-regulated
with HSP70-2 shRNA3 (P < 0.001; P < 0.002) and shRNA4
(P < 0.0001; P < 0.005) compared to HSP70-2 shRNA1,
shRNA2 and NC shRNA (Fig. 2a) in MCF7 and MDA-
MB-231 cells respectively. Therefore, in all subsequent in-
vitro assays, HSP70-2 shRNA3 and shRNA4 targets were
used in cell culture. Our cell proliferation studies revealed
a significant reduction in cell count by 46.7 % (P < 0.0001)
and 41.5 % (P < 0.0001) respectively in HSP70-2 shRNA3
and shRNA4 transfected MCF7 cells post 72h respectively
as compared to NC shRNA transfected cells (Fig. 2b).
Expectedly, MDA-MB-231 cells also showed reduction in
cell count by 48.4 % (P < 0.05) in HSP70-2 shRNA3
transfected cells and 43.9 % (P < 0.001) in HSP70-2
shRNA4 transfected cells. Also, there was a significant
reduction (P < 0.001) in cell viability of HSP70-2 shRNA3
and shRNA4 transfected MCF7 and MDA-MB-231 cells
compared to NC shRNA transfected cells (Additional file 3:
Figure S2a). Importantly, HSP70-2 depletion also resulted
in a significant reduction in the colony forming ability
of MCF7cells by 60.79 % (P < 0.0001) with HSP70-2
shRNA3 and 63.16 % (P < 0.0001) with HSP70-2
shRNA4 transfection (Additional file 3: Figure S2b).
MDA-MB-231 cells also exhibited marked reduction of
60.01 % (P < 0.0001) and 63.87 % (P < 0.0001) in cells
transfected with HSP70-2 shRNA3 and shRNA4 res-
pectively (Additional file 3: Figure S2b). Thus, HSP70-2
seems to play an important role in cell proliferation,
cell viability and tumorigensis.
Knockdown of HSP70-2 results in cell cycle arrest and
induces senescence
Next we investigated the role of HSP70-2 in cell cycle.
We observed that down-regulation of HSP70-2 expression
led to accumulation of MDA-MB-231 cells in G0/G1
phase in HSP70-2 shRNA3 and shRNA4 treated cells
(Fig. 2c and Additional file 3: Figure S2c). Further, phase
contrast microscopy of these cells showed enhanced β-
galactosidase staining in HSP70-2 depleted MDA-MB-231
cells (green color; Fig. 2d), while scanning electron mi-
croscopy (SEM) images showed flattened phenotype of
these cells compared to normal (Fig. 2d ). Besides, HSP70-
2 depleted MDA-MB-231 cells showed increased onset of
senescence (P < 0.001; Fig. 2d) as also evident from en-
hanced expression of senescence associated marker, Decoy
receptor 2 (DCR2) and lamin B1 in these cells (Fig. 2e).
Thus, these results suggested that depletion of HSP70-2
seems to initiate senescence process.
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We further examined the status of molecules involved
in cell cycle arrest. Our qPCR results in HSP70-2
depleted MDA-MB-231 cells revealed 1.6 fold up-
regulation of p21 expression (P < 0.019) with a concomi-
tant reduction in CDK1 (P < 0.007), CDK2 (P < 0.009),
CDK4 (P < 0.0003), CDK6 (P < 0.006), cyclin B1 (P < 0.027),
cyclin D1 (P < 0.007) and cyclin E levels (P < 0.008;
Additional file 3: Figure S2d). Further, Western blot
analysis confirmed the over-expression of CDK inhibi-
tors, p21 and decreased expression of cyclin D1, cyclin E,
CDK4 and CDK6 and reduced expression of G2/M-phase
CDK1, CDK2 and cyclin B1 and cyclin A2 in HSP70-2 de-
pleted cells (Fig. 2e). We also observed decreased levels of
phosphorylated Rb and corresponding accumulation of Rb
due to G0/G1 arrest of the cells. As expected, proliferating
cell nuclear antigen (PCNA) expression also decreased as
shown in Fig. 2e. Collectively, these results suggested that
G0/G1 arrest caused by ablation of HSP70-2 may be medi-
ated through up-regulation of p21 and down-regulation of
cyclins and their cognate kinases.
HSP70-2 gene silencing initiates apoptosis
The phenotypic changes associated with apoptosis were
investigated by SEM in HSP70-2 depleted MCF7 and
MDA-MB-231 cells. Post 24 h, both breast cancer cells ex-
hibited early signs of apoptosis including cell shrinkage and
blebbing, followed by the formation of apoptotic bodies in
HSP70-2 shRNA3 and shRNA4 transfected cells (Fig. 3a).
Post 48 h, most of the cells appeared to undergo apoptotic
death. However, no phenotypic changes in the morphology
of NC shRNA transfected (Fig. 3a) and lipofectamine
treated cells were observed (Additional file 4: Figure S3a).
To elucidate the role of HSP70-2 in apoptosis, we
analyzed several characteristic markers of apoptosis in
Fig. 2 HSP70-2 protein ablation arrests cell cycle growth and induces cellular senescence in breast cancer cells. a Quantitative-PCR and Western
blot analysis shows maximum HSP70-2 ablation with shRNA3 and shRNA4 transfected MCF7 and MDA-MB-231 cells compared to NC shRNA, shRNA1
and shRNA2 transfected cells. b Histogram depicts significant reduction in cellular proliferation after 24, 48 and 72 h in shRNA3 and shRNA4 transfected
MCF7 and MDA-MB-231 cells compared to NC shRNA transfected cells. c Histogram depicts the accumulation of cells in G0/G1 phase in MDA-MB-231
cells transfected with shRNA3 and shRNA4 compared to NC shRNA. d Phase contrast (left panel) and SEM (right panel) images show onset of
senescence as shown by β-galactosidase staining (green color) and flattened morphology, respectively in shRNA3 and shRNA4 transfected
MDA-MB-231 cells compared to NC shRNA. Inset shows zoom image of selected region from the core. Histogram demonstrates percentage of
cells observed under phase contrast microscopy images undergoing senescence when transfected with NC shRNA, shRNA3 and shRNA4.
Phase contrast microscopy: Original magnification ×100, objective ×10. SEM: Magnification: ×700, WD = 6 mm, EHT = 20.00 kV. e Western blot
analysis showed decreased expression of CDK4, CDK6, Cyclin D1, Cyclin E, pRb, PCNA, CDK1, CDK2, Cyclin A2, Cyclin B1, Lamin B1, while increased
expression of p21, Rb, DcR2 in shRNA3 and shRNA4 transfected MDA-MB-231 cells compared to NC shRNA. The three independent experiments were
carried out in triplicates. Data are represented as mean ± SEM. *P < 0.05, **P < 0.001, ***P < 0.0001
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HSP70-2 depleted cells. We analyzed annexinV staining
to examine the externalization of phosphatidyl serine,
an early sign of apoptosis. Our flow cytometry data
showed marked increase in annexinV staining in MDA-
MB-231 cells transfected with HSP70-2 shRNA3 and
shRNA4 as compared to NC shRNA (Fig. 3b). We also
determined changes in the mitochondrial membrane
potential (MMP) of HSP70-2 depleted MDA-MB-231
cells using TMRE (tetramethyl rhodamine, ethyl ester)
dye. Our data revealed loss of potential due to HSP70-2
Fig. 3 HSP70-2 depletion results in apoptosis of breast cancer cells. a Representative SEM images show onset of apoptosis characterized by membrane
blebbing, holes and apoptotic bodies formation in shRNA3 and shRNA4 transfected MCF7 and MDA-MB-231 cells compared to NC shRNA transfected
cells. Magnification: ×2000, WD = 6 mm, EHT = 20.00 kV. b Flow cytometric analysis shows increased number of MDA-MB-231 cells bound to annexinV
when transfected with shRNA3 and shRNA4 compared to NC shRNA transfected cells. c Flow cytometric data demonstrates loss of mitochondrial
membrane potential in MDA-MB-231 cells transfected with shRNA3 and shRNA4 compared to NC shRNA transfected cells. d Flow cytometric analysis
depicts increased number of MDA-MB-231 cells expressing M30 on their surface when transfected with shRNA3 and shRNA4 compared to NC shRNA
transfected cells. e FACS data shows increased DAPI intensity in MDA-MB-231 cells transfected with shRNA3 and shRNA4 compared to NC shRNA. f FACS
analysis demonstrates increased apo-BrdU staining in shRNA3 and shRNA4 transfected MDA-MB-231 cells compared to NC shRNA transfected
cells. g Western blot analysis shows up-regulation of pro-apoptotic (BAX, BAK, BAD, NOXA, BID, cytochrome-C, PUMA, PARP1, AIF, APAF1,
Caspase 3, Caspase 6, Caspase 7, Caspase 9) molecules and down-regulation of anti-apoptotic molecules (BCL2, BCL-xL, cIAP2, MCL1, Survivin,
XIAP, GRP78) in HSP70-2 depleted MDA-MB-231 cells. The three independent experiments were carried out in triplicates
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shRNA treatment (Fig. 3c). Next, we investigated cas-
pase cleavage by employing M30 assay and found
higher population of M30 positive (Fig. 3d). To monitor
the late apoptosis events, we also examined chromatin
condensation by DAPI staining and observed a rise in
the DAPI intensity in HSP70-2 depleted MDA-MB-231
cells (Fig. 3e). In addition, we examined DNA fragmen-
tation by TUNEL assay and observed a marked increase
in BrdU positive MDA-MB-231cells (Fig. 3f ).
Analysis of pro-apoptotic gene expression by qPCR in
HSP70-2 shRNA4 treated cells revealed a significant in-
crease in the expression of BID (P < 0.003), caspase 6
(P < 0.033), caspase 7 (P < 0.008), caspase 9 (P < 0.012),
PUMA (P < 0.002) and cytochrome-C (P < 0.007) by
1.39, 1.83, 1.72, 1.89, 3.0 and 1.92 folds respectively.
Whereas the expression of anti-apoptotic molecules
including BCL2 (P < 0.003), BCL-xL (P < 0.045), Survivin
(P < 0.009), cIAP2 (P < 0.003), XIAP (P < 0.035) and
MCL1 (P < 0.007) was significantly inhibited (Additional
file 4: Figure S3b). Further, Western blot analysis re-
vealed increased expression of molecules involved in
intrinsic pathway including caspase 3, caspase 6, cas-
pase 7, caspase 9 and cytochrome-C (Fig. 3g). The
levels of pro-apoptotic molecules including BID, BAD,
BAK, BAX, NOXA, APAF1 and PUMA were also up-
regulated in these cells. As expected, low level of ex-
pression of several anti-apoptotic molecules including
BCL2, BCL-xL, Survivin, MCL1 and XIAP was observed
(Fig. 3g). Interestingly, increased expression of AIF and
PARP-1 in these cells suggested the activation of
caspase-independent pathway under these conditions
(Fig. 3g). Considering the important role of HSP70-2 in
protein folding and degradation, activation of intrinsic
apoptotic pathway due to HSP70-2 abrogation prompted
us to investigate whether the ER stress could be the
underlying cause of pro-apoptotic cell death. We did find
decrease protein expression of ER chaperone protein,
GRP78 in HSP70-2 depleted cells (Fig. 3g) suggesting its
essential role in cell survival.
HSP70-2 is essential for cellular motility, migration
and invasion
Increased cellular motility, migration and invasion are
distinguishing features of cancer cells. We studied trans-
well membrane assays to study the effect of ablation of
HSP70-2 on migratory and invasive properties of MCF7
and MDA-MB-231cells. The cell migration assay exhibi-
ted a significant reduction (P < 0.05) in the migration of
HSP70-2 shRNA3 and shRNA4 transfected cells com-
pared to NC shRNA (Fig. 4a, b) with a concomitant loss
of invasive ability through matrigel (P < 0.05, Fig. 4c, d).
Further, the SEM images of transwell membranes con-
firmed reduced migration of these cells (Fig. 4e, f ). In
addition, wound healing assay also indicated reduced
cellular motility under the conditions as compare to
control cells (Additional file 5: Figure S4a).
Epithelial-Mesenchymal Transition (EMT) is considered
to be a benchmark in cancerous growth. Therefore, we
measured the mRNA expression of EMT markers in
HSP70-2 depleted cells. As shown in Additional file 5:
Figure S4b, there was an overall significant reduction in
the mRNA levels of mesenchymal markers such as N-
Cadherin (P < 0.0001), P-Cadherin (P < 0.012), MMP2
(P < 0.0001), MMP3 (P < 0.004), SLUG (P < 0.006), SNAIL
(P < 0.049), Vimentin (P < 0.005) and SMA (P < 0.010).
However the epithelial cell marker, E-Cadherin (P < 0.002),
showed an increased expression of 2.74 fold (Additional
file 5: Figure S4b). Further, Western blot analysis validated
our qPCR data revealing down-regulation of SNAIL,
SLUG and TWIST (EMT regulators) along with SMA,
Vimentin, N-Cadherin, P-Cadherin, MMP2, MMP3 and
MMP9 (Fig. 4g). As expected, there was increase in E-
Cadherin expression (Fig. 4g). Thus, HSP70-2 seems to
play an important role in cellular migration and inva-
sion orchestrated via EMT pathway.
Depletion of HSP70-2 causes reduced xenograft breast
tumor growth in-vivo
To validate our finding on HSP70-2 in cell culture, we
studied the effect of ablation of HSP70-2 on tumor
growth in xenograft mouse model. As shown in Fig. 5a,
there was a reduction in tumor size in HSP70-2 shRNA4
treated mice compared to NC shRNA treated mice. The
tumor weight and volume of mice injected with HSP70-2
shRNA4 was significantly reduced (P < 0.001) as com-
pared control animals (Fig. 5b, c). Western blot analysis of
xenograft tissue sections showed that HSP70-2 protein
and PCNA was reduced post HSP70-2 shRNA4 adminis-
tration (Fig. 5d). Further, IHC analysis of excised tumor
sections confirmed reduction in HSP70-2 and PCNA
expression (Fig. 5e).
We further examined these tumor sections to under-
stand changes in the molecules involved in various path-
ways following HSP70-2 depletion by IHC. In agreement
with our in-vitro data, the IHC analysis showed in-
creased expression of CDK inhibitor, p21 in mice admin-
istered with HSP70-2 shRNA4 compared to NC shRNA
treated mice (Fig. 5e). This was accompanied with de-
creased expression of CDKs including CDK1, CDK2,
CDK4 and CDK6, cyclins including cyclin A2, cyclin B1,
cyclin D1 and cyclin E in tumors treated with HSP70-2
shRNA4 in contrast to NC shRNA. Next, we compared
the expression of molecules involved in apoptosis in
HSP70-2 shRNA4 and NC shRNA treated tumor (Fig. 6).
Notably, most of the key molecules of apoptotic pathway
showed increased expression of caspase 3, caspase 6,
caspase 7, caspase 9, cytochrome-C, APAF1, BAD, BAX,
BID, PUMA and NOXA in HSP70-2 shRNA treated
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tumors (Fig. 6). This was also concomitant with down-
regulation of several anti-apoptotic molecules, BCL2,
BCL-xL, MCL1, Survivin, cIAP2 and XIAP (Fig. 6). In
addition, caspase independent AIF mediated cell death
also increased as revealed by increased expression of
AIF and PARP1 in HSP70-2 shRNA treated compared to
NC shRNA treated tumors (Fig. 6). Also we found, reduc-
tion in expression of glucose-regulated protein, GRP78 in
tumors treated with HSP70-2 shRNA4 (Fig. 6).
We further investigated the expression of EMT regu-
lators. We observed reduction in the expression of
EMT regulator SNAIL, in consequence to the ablation
of HSP70-2. In addition, there was a decreased expres-
sion of mesenchymal markers such as N-Cadherin, P-
Cadherin, Vimentin, SNAIL, SLUG, TWIST and SMA
in HSP70-2 shRNA4 treated tumor compared to NC
shRNA treated tumors. HSP70-2 ablation also revealed in-
crease in epithelial marker, E-Cadherin expression (Fig. 6).
Fig. 4 HSP70-2 ablation inhibits cellular motility of breast cancer cells. a Phase contrast microscopy images show difference in number of
MCF7 and MDA-MB-231 cells migrating through the transwell-insert membrane when transfected with shRNA3, shRNA4 compared to NC shRNA.
b Histogram demonstrates significant reduction in number of migratory MCF7 and MDA-MB-231 cells transfected with shRNA3 and shRNA4
compared to NC shRNA. c Phase contrast microscopy images depict reduced number of MCF7 and MDA-MB-231 cells invading through matrigel
coated transwell insert membrane when transfected with shRNA3 and shRNA4 compared to NC shRNA. d Histogram shows significantly reduced
number of shRNA3 and shRNA4 transfected MCF7 and MDA-MB-231 cells invading through insert as compared to NC shRNA. *P < 0.05. Data are
represented as mean ± SEM. e SEM images show difference in the number of MCF7 (first panel) and MDA-MB-231 (second panel) cells migrating
through transwell insert membrane when transfected with shRNA3 and shRNA4 compared to NC shRNA in migration. Magnification: ×700,
WD = 6 mm, EHT = 20.00 kV. Third panel shows single MDA-MB-231 cell migrating through the transwell insert membrane. Magnification: ×4000,
WD = 6 mm, EHT = 20.00 kV. f SEM images depict difference in the number of MCF7 (first panel) and MDA-MB-231 (second panel) cells invading
through transwell insert membrane when transfected with shRNA3 and shRNA4 compared to NC shRNA. Magnification: ×700, WD = 6 mm,
EHT = 20.00 kV. Third panel shows single MDA-MB-231 cell invading through the transwell insert membrane. Magnification: ×4000, WD = 6 mm,
EHT = 20.00 kV. The three independent experiments were carried out in triplicates. g Western blot analysis demonstrates up-regulation of epithelial
marker (E-Cadherin) and down-regulation of mesenchymal markers (N-Cadherin, P-Cadherin, MMP2, MMP3, MMP9, SLUG, SNAIL, TWIST, SMA, Vimentin)
in HSP70-2 depleted MDA-MB-231 cells
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Our data revealed that HSP70-2 shRNA4 treated tumors
exhibited decreased expression of MMP2, MMP3 and
MMP9 (Fig. 6). To validate our IHC finding, we employed
qPCR to check mRNA expression of several key molecules
in HSP70-2 shRNA4 treated tumors, relative to the NC
shRNA treated tumors. It is interesting to note that our
qPCR results were consistent with IHC analysis. Ini-
tially we checked the relative level of mRNA of HSP70-
2 in HSP70-2 shRNA4 treated tumors and NC shRNA
treated tumors and found a marked depletion of HSP70-2
mRNA expression upon shRNA mediated gene silencing
(Additional file 6: Figure S5a). There was a reduction in
CDK1 (P < 0.028), CDK2 (P < 0.039), CDK, 4 (P < 0.001),
CDK6 (P < 0.016), cyclin B1 (P < 0.001), cyclin D1 (P <
0.001) and cyclin E (P < 0.001) expression, relative to the
NC shRNA treated tumors (Additional file 6: Figure S5b).
Our qPCR study on apoptotic molecules in HSP70-2
shRNA4 treated tumors revealed an increase expres-
sion of BAD (P < 0.004), caspase 6 (P < 0.029), caspase
7 (P < 0.007), caspase 9 (P < 0.016), PUMA (P < 0.008),
NOXA (P < 0.001) and cytochrome-C (P < 0.001). Also
decreased expression of anti-apoptotic molecules in-
cluding BCL2 (P < 0.001), BCL-xL (P < 0.001), Survivin
(P < 0.028), MCL1 (P < 0.005) and cIAP2 (P < 0.001)
were found (Additional file 6: Figure S5c). Comparison of
mRNA expression of EMT molecules in HSP70-2 shRNA
treated tumors and NC shRNA treated tumors revealed
decreased expression of SLUG (P < 0.013), P-Cadherin
(P < 0.038), N-Cadherin (P < 0.001), MMP3 (P < 0.001),
MMP9 (P < 0.001), SMA (P < 0.029) and SNAIL (P < 0.008).
However, E-Cadherin (P < 0.001), displayed increased ex-
pression of 2.55 fold in HSP70-2 shRNA treated mice
(Additional file 6: Figure S5d). Interestingly, our IHC
data and qPCR results showed similar results.
Fig. 5 HSP70-2 shRNA treatment reduces tumor growth of human breast cancer xenograft. a Representative image shows reduced tumor size of
the mice treated with shRNA4 (n = 8) compared to NC shRNA (n = 8). b Histogram shows significant difference in weight of tumor when treated
with shRNA4 compared to NC shRNA. c Line graph shows significant difference in tumor volume when treated with shRNA4 compared to NC shRNA.
d Western blot analysis depicts decreased expression of HSP70-2 and PCNA in shRNA4 treated tumor as compared to NC shRNA. e Representative
images show IHC analysis of serial sections of shRNA4 and NC shRNA treated tumor for HSP70-2, PCNA and cell cycle molecules (CDK1, CDK2, CDK4,
CDK6, Cyclin A2, Cyclin B1, Cyclin D1, Cyclin E, p21). H&E staining shows cytostructure of the tumor cells. Objective: ×20, Magnification: ×200. *P < 0.05,
**P < 0.001. Data are represented as mean ± SEM
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Collectively, our results indicated that HSP70-2 con-
tributes in cellular proliferation, cellular migration and
invasion and its depletion causes significant reduction in
these processes both in-vitro and in-vivo xenograft mouse
model.
Discussion
Breast cancer is the most common cancer in women
worldwide and is the second leading cause of cancer-
related death in women [1]. Among various histotypes
of breast cancer, infiltrating ductal carcinoma (IDC) is
the most common histotype of breast cancer in which
cancer cells invade through the ductal wall into the
stroma [2]. Therefore, the present study was under-
taken to investigate the role of a novel cancer testis
(CT) antigen, HSP70-2 expression and its potential in-
volvement in breast cancer patients and in various
breast cancer cell line models. We found that majority
of breast cancer patients [83 % (128/154), Table 1]
showed HSP70-2 expression irrespective of stages,
grades and histotypes. More importantly, we also found
significant association of HSP70-2 expression with
grades. In addition, HSP70-2 expression was observed
in majority of patients with positive lymph node in-
volvement suggesting a role of HSP70-2 in tumor mi-
gration and invasion. Our data from various breast
cancer cell lines were broadly in agreement with our
in-vivo studies in xenograft model. Earlier studies in
small number of breast cancer specimens [36 % (9/25)]
also revealed HSP70-2 expression [8]. Moreover our re-
cent studies on well characterized CT antigens, SPAG9
and AKAP4 have shown their association with breast
cancer cases [14, 15]. The other CT antigens family
member, MAGE-A9 and MAGE-A11 have also been
found to be expressed in breast cancer specimens [16].
Our current findings in various stages and grades of
breast cancer tumors suggest that HSP70-2 may be in-
volved in various signaling pathways and control cellu-
lar proliferation, dysregulation of cell cycle, migration
and invasion abilities in cancer cells.
Fig. 6 HSP70-2 depletion in MDA-MB-231 tumor cells initiates apoptosis and inhibits EMT in tumor xenograft. Representative IHC images show
altered expression of apoptotic molecules (BAD, BAX, BID, PUMA, NOXA, Cytochrome-C, Caspase 3, Caspase 6, Caspase 7, Caspase 9, APAF1, AIF,
PARP1, BCL2, BCL-xL, MCL1, cIAP2, XIAP, Survivin, GRP78), epithelial (E-Cadherin) and mesenchymal markers (N-Cadherin, P-Cadherin, SLUG, SMA,
SNAIL, TWIST, Vimentin, MMP2, MMP3, MMP9) in sections of tumor treated with shRNA4 and NC shRNA. Objective: ×20, Magnification: ×200
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Altered expression of cell-cycle-regulatory proteins is a
major abnormalities during cancer [17]. It may involve
over-expression of cyclins and cyclin dependent kinases
(CDK) or mutation of tumor suppressor genes [18]. A
earlier report has shown that HSP70-2 is a binding part-
ner of cdk1/cyclinB complex during meiotic division in
spermatogenesis [19]. The present study shows that ab-
lation of HSP70-2 resulted in accumulation of cancer
cells in G0/G1 stage. In support of our observation, simi-
lar findings have been reported in HSP70-2 depleted
HeLa cells [8]. Our results further revealed that mole-
cules involved in cell cycle (cyclins: cyclin A2, cyclin B1,
cyclin D1 and cyclin E along with CDKs: CDK1, CDK2,
CDK4 and CDK6) were downregulated in HSP70-2 de-
pleted MDA-MB-231 cells. Interestingly, we also found
that senescence was associated with G0/G1 arrest with
increased expression of p21, Rb and DCR2 (senescence
marker). In this context, it may be possible that the
HSP70-2 expression may play an important role in alter-
ation of cell cycle regulation molecules resulting in un-
controlled cellular proliferation.
Failure in process of apoptosis results in cancer disease
[17]. The cell death occurs due to initiation of apoptosis
which includes well regulated expression of pro- and
anti-apoptotic molecules of the Bcl-2 family as regula-
tory proteins [17]. Over-expression of BCL-2 has been
found in 60–80 % of breast carcinoma suggesting its role
in breast cancer [20]. The current study showed significant
increase in cell death in HSP70-2 depleted MDA-MB-231
and MCF7 cells. Our observations further supported that
cancer cell death occurred due to decreased expression in
anti-apoptotic molecules (BCL-xL, BCL2, Survivin, XIAP2,
cIAP2, MCL1) and increased expression in pro-apoptotic
molecules (caspase 3, caspase 6, caspase 7, caspase 9, BAX,
BAK, BAD, NOXA, BID, cytochrome-C, PUMA, APAF1,
AIF, and PARP1) in HSP70-2 depleted MDA-MB-231 cells.
Similar findings on BORIS-specific siRNA treatment in-
duced caspase 3/7 activation in a dose dependent manner
in MDA-MB-231 cells [21] lead to cell death indicating its
role in survival of cancer cells. Interestingly, recent studies
have shown the role of yet another important molecule, un-
folded protein response (UPR) which is upregulated in
triple negative breast cancer (TNBC) [22]. Interestingly, our
report on HSP70-2 ablated in TNBC, MDA-MB-231 cells
lead to decrease expression of glucose-regulated protein
(GRP78), which is a master regulator of UPR and has
been associated with cancer disease and drug resistance
[23]. Collectively, our study indicates that ablation of
HSP70-2 in breast cancer cells promotes apoptosis and
hence cancer cell death.
Our most important findings suggest that HSP70-2 ex-
pression in breast cancer cells play an important role in
cellular growth, cell migration, and invasion. Epithelial-
Mesenchymal transition (EMT) is considered to be the
important pathway involved in migration and invasion
of cancer cells to distant sites [17]. Expression of pro-
teins characteristic of mesenchymal cells (N-Cadherin,
Vimentin, SNAIL, SLUG) and loss of epithelial markers
(E-Cadherin) correlates with tumor progression and poor
prognosis [24]. Our observations supported previous
studies [24] wherein HSP70-2 ablation in the present
study effected cancer cell migration and invasion potential
in MDA-MB-231 and MCF7 cells. Supported by previous
findings [24], our data also revealed that various mesen-
chymal markers like N-Cadherin, P-Cadherin, MMP2,
MMP3, MMP9, SLUG, TWIST, Vimentin, and SMA were
down-regulated with increased expression of E-Cadherin
in HSP70-2 depleted MDA-MB-231 cells. Recent studies
on CT antigens such as SSX, MAGED4B, CAGE and
piwil2 showed up-regulation of EMT and metastatic genes
expression that promote tumor dissemination [25]. A re-
cent study also showed that over-expression of CT45A1,
CT antigen in breast cancer cells selectively enhanced
the expression of pro-EMT gene, including TWIST1,
ALDH1A1 [26]. On similar lines, our data suggests that
HSP70-2 depletion in breast cancer cells contributes in
reduced cancer cell motility by inhibiting molecules
involved in EMT pathway.
In summary, this investigation of well characterized hu-
man breast cancer tissues (103 ANCT and n = 154 cancer
tissue) has documented that HSP70-2 expression is over
expressed in breast cancer patients. Furthermore, our data
demonstrated that plasmid-mediated RNA interference of
HSP70-2 successfully inhibited the expression of HSP70-2
in in-vitro and in-vivo models of breast cancer, leading to
inhibitory effects on cell proliferation, migration, invasion,
and tumor growth. In this regard, recent, clinical trials
employing gene silencing approach has shown a promise
in developing new class of therapeutics [27]. Collectively,
our findings suggest that the shRNA mediated gene silen-
cing approach may be an effective therapeutic strategy as
an adjuvant therapy or in combination with other treat-
ment modalities for breast cancer and therefore warrant
future investigations in human clinical trials.
Conclusions
Taken together, our study indicated that HSP70-2 might
be playing an important role in development and pro-
gression of breast cancer. Gene silencing approach indi-
cated that HSP70-2 promotes cell growth and cellular
motility of breast cancer cells. Also, HSP70-2 depletion
led to reduction in tumor growth in in-vivo human
breast cancer xenograft model. Recent clinical trials on
siRNA based therapy [27] indicated that gene silencing
approach has a potential to be employed in cancer therapy.
Thus, HSP70-2 may be considered as potential candidate
molecule in the management of breast cancer patients and
warrants future studies.
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